D
Elutia Inc.
ELUT
$2.71
-$0.20-6.87%
D
Sell
1/16/2024Upgraded
Elutia Inc. (ELUT) was upgraded to D- from E+ on 1/16/2024 due to a major increase in the growth index, volatility index and total return index. Total revenue increased 2,095.77% from -$307 to $6.13M, EBIT increased 52.93% from -$6.96M to -$3.28M, and earnings per share increased from -$0.6549 to -$0.5728.
Elutia Inc. (ELUT) was upgraded to D- from E+ on 1/16/2024 due to a major increase in the growth index, volatility index and total return index. Total revenue increased 2,095.77% from -$307 to $6.13M, EBIT increased 52.93% from -$6.96M to -$3.28M, and earnings per share increased from -$0.6549 to -$0.5728.
E
Sell
3/15/2023Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D- on 3/15/2023 due to a decline in the total return index.
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D- on 3/15/2023 due to a decline in the total return index.
D
Sell
3/2/2023Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to D- from D on 3/2/2023 due to a decline in the total return index and volatility index.
Aziyo Biologics, Inc. (AZYO) was downgraded to D- from D on 3/2/2023 due to a decline in the total return index and volatility index.
D
Sell
2/9/2023Upgraded
Elutia Inc. (ELUT) was upgraded to D from E+ on 02/09/2023.
Elutia Inc. (ELUT) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 2/8/2023 due to a significant decline in the solvency index, growth index and total return index. Debt to equity increased from -15.79 to -1.87, operating cash flow declined 65.91% from -$3.32M to -$5.52M, and the quick ratio declined from 0.67 to 0.38.
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 2/8/2023 due to a significant decline in the solvency index, growth index and total return index. Debt to equity increased from -15.79 to -1.87, operating cash flow declined 65.91% from -$3.32M to -$5.52M, and the quick ratio declined from 0.67 to 0.38.
D
Sell
5/16/2022Upgraded
Aziyo Biologics, Inc. (AZYO) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.8179 to -$0.6003, EBIT increased 10.82% from -$7.76M to -$6.92M, and total revenue increased 5.84% from $10.86M to $11.5M.
Aziyo Biologics, Inc. (AZYO) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.8179 to -$0.6003, EBIT increased 10.82% from -$7.76M to -$6.92M, and total revenue increased 5.84% from $10.86M to $11.5M.
E
Sell
5/13/2022Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
Aziyo Biologics, Inc. (AZYO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
Aziyo Biologics, Inc. (AZYO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
E
Sell
5/1/2022Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Aziyo Biologics, Inc. (AZYO) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
Aziyo Biologics, Inc. (AZYO) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 4/20/2022 due to a decline in the valuation index.
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
3/15/2022Upgraded
Aziyo Biologics, Inc. (AZYO) was upgraded to D from D- on 3/15/2022 due to a noticeable increase in the growth index, total return index and solvency index. Debt to equity declined from 2.81 to 1.72, and the quick ratio increased from 1.25 to 1.4.
Aziyo Biologics, Inc. (AZYO) was upgraded to D from D- on 3/15/2022 due to a noticeable increase in the growth index, total return index and solvency index. Debt to equity declined from 2.81 to 1.72, and the quick ratio increased from 1.25 to 1.4.
D
Sell
11/15/2021Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to D- from D on 11/15/2021 due to a noticeable decline in the growth index, valuation index and solvency index. Operating cash flow declined 293.65% from -$787 to -$3.1M, earnings per share declined from -$0.2332 to -$0.8125, and debt to equity increased from 1.61 to 2.81.
Aziyo Biologics, Inc. (AZYO) was downgraded to D- from D on 11/15/2021 due to a noticeable decline in the growth index, valuation index and solvency index. Operating cash flow declined 293.65% from -$787 to -$3.1M, earnings per share declined from -$0.2332 to -$0.8125, and debt to equity increased from 1.61 to 2.81.
D
Sell
11/9/2021Upgraded
Elutia Inc. (ELUT) was upgraded to D from E+ on 11/09/2021.
Elutia Inc. (ELUT) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
Aziyo Biologics, Inc. (AZYO) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
11/3/2021Upgraded
Aziyo Biologics, Inc. (AZYO) was upgraded to D from D- on 11/3/2021 due to an increase in the growth index, valuation index and solvency index. Operating cash flow increased 84.79% from -$5.17M to -$787, earnings per share increased from -$0.4955 to -$0.2332, and debt to equity declined from 1.68 to 1.61.
Aziyo Biologics, Inc. (AZYO) was upgraded to D from D- on 11/3/2021 due to an increase in the growth index, valuation index and solvency index. Operating cash flow increased 84.79% from -$5.17M to -$787, earnings per share increased from -$0.4955 to -$0.2332, and debt to equity declined from 1.68 to 1.61.
D
Sell
7/1/2021Upgraded
Aziyo Biologics, Inc. (AZYO) was upgraded to D- from E on 7/1/2021 due to a large increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.5702 to -$0.4955, net income increased 5.4% from -$5.36M to -$5.07M, and operating cash flow increased 3.61% from -$5.37M to -$5.17M.
Aziyo Biologics, Inc. (AZYO) was upgraded to D- from E on 7/1/2021 due to a large increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.5702 to -$0.4955, net income increased 5.4% from -$5.36M to -$5.07M, and operating cash flow increased 3.61% from -$5.37M to -$5.17M.
E
Sell
4/1/2021Upgraded
Aziyo Biologics, Inc. (AZYO) was upgraded to E from E- on 4/1/2021 due to a significant increase in the solvency index and total return index. The quick ratio increased from 0.34 to 1.73.
Aziyo Biologics, Inc. (AZYO) was upgraded to E from E- on 4/1/2021 due to a significant increase in the solvency index and total return index. The quick ratio increased from 0.34 to 1.73.
E
Sell
1/4/2021None
Elutia Inc. (ELUT) was downgraded to E- from U on 01/04/2021.
Elutia Inc. (ELUT) was downgraded to E- from U on 01/04/2021.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
